the fiscal third quarter of 2023, the Company is now organized into
two
reportable segments: Innovative Medicine and MedTech. The segment results have been recast for all periods to reflect the continuing operations of the Company.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
*    percentage greater than 100% or not meaningful
(1)
Previously referred to as Interventional Solutions
(2)
Acquired on December 22, 2022
(3)
Acquired on May 31, 2024
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2024, the Company utilized three wholesalers distributing products for both segments that represented approximately
20.5
%,
15.6
% and
12.3
% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately
18.2
%,
15.1
% and
14.2
% of the total gross revenues. In fiscal year 2022, the Company had three wholesalers distributing products for all
three
segments that represented approximately
18.9
%,
15.0
%, and
13.8
% of the total gross revenues.
(1)
Other segment expenses
for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(2)
Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal years 2024 and 2023 include charges for talc matters of approximately $
5.1
billion and $
7
billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $
0.4
billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $
0.4
billion.
(3)
Innovative Medicine segment income before tax includes:
•
Acquired in-process research & development expense of $
1.25
billion to secure the global rights to the NM26 bispecific antibody (Yellow Jersey acquisition)
•
Monetization of royalty rights of $
0.3
billion
•
Litigation expense of $
0.3
billion primarily related to Risperdal Gynecomastia
•
An intangible asset impairment charge of approximately $
0.2
billion associated with the M710 (biosimilar) asset acquired as part of the acquisition of Momenta Pharmaceuticals in 2020.
•
A restructuring related charge of $
0.1
billion
•
One-time COVID-19 Vaccine manufacturing